Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OncoMed Signs Second Cancer Stem Cell Partner; This Time It's Bayer

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal with Bayer to discover and develop Wnt pathway therapies follows 2007 deal with GSK focused on Notch pathway.

You may also be interested in...



Verastem Joins The Public Markets With A Strong IPO

Verastem IPO’d at $10 per share on Jan. 26, despite having only preclinical assets in its pipeline. Strong interest from large companies for cancer stem cell therapies helped contribute to the price.

At PSA, Meet The New Deal-Makers (Part 2)

At EBI's Pharmaceutical Strategic Alliances conference in New York on Sept. 22, BD experts addressed key issues for their profession as pharma revamps the way it balances internal and external R&D.

At PSA, Meet The New Deal-Makers (Part 2)

At EBI's Pharmaceutical Strategic Alliances conference in New York on Sept. 22, BD experts addressed key issues for their profession as pharma revamps the way it balances internal and external R&D.

Topics

Latest News
UsernamePublicRestriction

Register

PS070770

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel